The Effect of n-3 Fatty Acids on Lipids and Haemostasis in Patients with Type lla and Type IV Hyperlipidaemia

Summary

Plasma lipids and haemostasis were investigated in 17 patients with hyperlipidaemia before and after 6 weeks supplementation with 6 g n-3 fatty acids. Nine of the patients had type IIa and 8 had type IV hyperlipidaemia. No effect on plasma cholesterol, LDL- or HDL-cholesterol were seen, but plasma triglycerides decreased after n-3 supplementation. Apolipoprotein B increased and apolipoprotein A₁ decreased after the oil supplement. The bleeding time was prolonged, but platelet aggregation was unaltered by n-3 fatty acids. Protein C activity increased in type II a and decreased in type IV after the supplement. Fibrinolysis was markedly depressed while von Willebrand factor antigen was reduced after intake of n-3 fatty acids.

Keywords

n-3 fatty acids - Fish oil - Lipids - Haemostasis - Fibrinolysis

• References

• 1 Carlson LA, Böttinger LE. Risk factors for ischaemic heart disease in men and woman. Acta Med Scand 1985; 218: 207-211
• 2 Castelli WP. The triglyceride issue: A view from Framingham. Am Heart J 1986; 112: 432-437
• 3 Dalaker K, Smith P, Arnesen H, Prydz H. Factor VH-phospholipid complex in male survivors of acute myocardial infarction. Acta Med Scand 1987; 222: 111-116
• 4 Ross R. The pathogenesis of atherosclerosis - an update. N Engl J Med 1986; 314: 488-500
• 5 Meade TW, Brozovic M, Chakrabarti RR, Haines AP, Imeson JD, Mellows S, Miller GJ, North WR S, Stirling Y, Thompson SG. Haemostatic function and ischaemic heart disease: Principal results of the Northwick Park heart study. Lancet 1986; ii: 533-537
• 6 Wilhelmsen L, Svardsudd K, Korsan-Bengtsen K, Larsson B, Welin L, Tibblin G. Fibrinogen as a risk factor for stroke and myocardial infarction. N Engl J Med 1984; 311: 501-505
• 7 Balleisen L, Schulte M, Assmann G, Epping PH, Van de Loo J. Coagulation factors and the progress of coronary heart disease. Lancet 1987; II: 461
• 8 Hamsten A, Walldius G, Szamosi A, Blomback M, De Faire U, Dahlén G, Landou G, Wiman B. Plasminogen activator inhibitor in plasma: risk factor for recurent myocardial infarction. Lancet 1987; ii: 3-9
• 9 Joist JH, Baker RK, Schonfeld G. Increases in vivo and in vitro platelet function in type II- and type IV-hyperlipoproteinemia. Thromb Res 1979; 15: 95-108
• 10 Shastri KM, Carvalho AC A, Lees RS. Platelet function and platelet lipid composition in the dyslipoproteinemias. J Lipid Res 1980; 21: 467-472
• 11 Corash I, Andersen J, Poindexter BJ, Schaefer EJ. Platelet function and survival in patients with severe hypercholesterolaemia. Arteriosclerosis 1981; 1: 443-448
• 12 Zahavi J, Betteridge JD, Jones NAG, Galton DJ, Kakkar VV. Enhanced in vivo platelet release reaction and malondialdehyde formation in patients with hyperlipidaemia. Am J Med 1981; 70: 59-64
• 13 Strano A, Davi G, Averna M, Rini GB, Novo S, Di Fede G, Mattina A, Notarbartolo A. Platelet sensitivity to prostacyclin and thromboxane production in hyperlipidemic patients. Thromb Haemostas 1982; 48: 18-20
• 14 Nordøy A, Brox JH, Holme S, Killie JE, Lenner RA. Platelets and coagulation in patients with familial hypercholesterolemia (type IIa). Acta Med Scand 1983; 213: 129-135
• 15 Tremoli E, Maderna P, Colli S, Morazzoni G, Sirtori M, Cesare R, Sirtori E. Increased platelet sensitivity and thromboxane B₂ formation in type II-hyperlipoproteinaemic patients. Eur J Clin Invest 1984; 14: 329-333
• 16 Prisco D, Rogasi PG, Paniccia R, Coppo M, Abbate R, Gensini GF, Neri Serneri GG. Altered lipid composition and thromboxane A₂ formation in platelets from patients affected by II a hyperlipoproteinemia. Thromb Res 1988; 50: 593-604
• 17 Simpson HC R, Meade TW, Stirling Y, Mann JI, Chakrabarti R, Woolf L. Hypertriglyceridaemia and hypercoagulability. Lancet 1983; i: 786-790
• 18 Mari D, Vigotti G, Vergani C, Mannucci PM. Hemostatic functions in hypoalpha and hyperbetalipoproteinemias. Thromb Haemostas 1983; 50: 624-625
• 19 Andersen P, Arnesen H, Hjermann I. Hyperlipoproteinaemia and reduced fibrinolytic activity in healthy coronary high-risk men. Acta Med Scand 1981; 209: 199-202
• 20 Hamsten A, Wiman B, De Faire U, Blomback M. Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction. N Engl J Med 1985; 313: 1557-1563
• 21 Dyerberg J. Linolenate-derived polyunsaturated fatty acids and prevention of atherosclerosis. Nutr Rev 1986; 44: 125-134
• 22 Leaf A, Weber PC. Cardiovascular effects of n-3 fatty acids. N Engl J Med 1988; 318: 549-557
• 23 Herold PM, Kinsella JE. Fish oil consumption and decreased risk of cardiovascular disease: a comparison of findings from animal and human feeding trials. Am J Clin Nutr 1986; 43: 566-598
• 24 Dyerberg J, Hjpme N. Quantitative plasma lipoprotein estimation by agarose gel electrophoresis. Clin Chem Acta 1970; 28: 203-208
• 25 Kristensen SD, Schmidt EB, Andersen HR, Dyerberg J. Fish oil in angina pectoris. Atherosclerosis 1987; 64: 13-19
• 26 Clauss A. Gerinnungsphysiologische Schnellmethode zur Bestimmung des Fibrinogens. Acta Haematol 1957; 17: 237-246
• 27 Schmidt EB, Kristensen SD, Sørensen PJ, Dyerberg J. Antithrombin III and protein C in stable angina pectoris - influence of dietary supplementation with polyunsaturated fatty acids. Scand J Clin Lab Invest 1988; 48: 469-473
• 28 Astrup T, Miillertz S. The fibrin plate method for estimating fibinolytic activity. Arch Biochem Biophys 1952; 40: 346-351
• 29 Brox JH, Killie JE, Østerud B, Holme S, Nordøy A. Effects of cod liver oil on platelets and coagulation in familial hypercholesterolemia (type IIa). Acta Med Scand 1983; 213: 137-144
• 30 Demke DM, Peters GR, Linet OI, Metzler CM, Klott KA. Effect of a fish oil concentrate in patients with hypercholesterolemia. Atherosclerosis 1988; 70: 73-80
• 31 Simons LA, Hickie JB, Balasubramaniam S. On the effects of dietary n-3 fatty acids on plasma lipids and lipoproteins in patients with hyperlipidaemia. Atherosclerosis 1985; 54: 75-88
• 32 Davidson MM, Liebson PR, Bagdade JD, Messer JV, Schoenberger JA. Marine lipid concentrate reduces coronary risk factors: double blind comparison with olive oil. JACC 1986; 7: 247A
• 33 Hatcher LF, Connor WE, Ullmann DO, Gowen DR, Flavell DP. Dietary fish oil in familial hypercholesterolemia: response to added cholesterol. Am J Clin Nutr 1987; 45: 858a
• 34 Singer P, Wirth M, Berger I, Voigt S, Gerike U, Gödiche W, Koberle V, Heine H. Influence on serum lipids, lipoproteins and blood pressure of mackerel and herring diet in patients with type IV and V hyperlipoproteinemia. Atherosclerosis 1985; 56: 111-118
• 35 Phillipson BE, Rothrock DW, Connor WE, Harris WS, Illingworth DR. Reduction of plasma lipids, lipoproteins and apoproteins by dietary fish oils in patients with hypertriglyceridemia. N Engl J Med 1985; 312: 1210-1216
• 36 Sanders TAB, Sullivan DR, Reeve J, Thompson GR. Triglyceridelowering effect of marine polyunsaturates in patients with hypertriglyceridemia. Arteriosclerosis 1985; 5: 459-465
• 37 Boberg M, Vessby B, Selinus I. Effects of dietary supplementation with n-6 and n-3 long-chain polyunsaturated fatty acids on serum lipoproteins and platelet function in hypertriglyceridaemic patients. Acta Med Scand 1986; 220: 153-160
• 38 Sullivan DR, Sanders TAB, Trayner IM, Thompson GR. Paradoxical elevation of LDL apolopoprotein B levels in hypertriglyceridaemic patients and normal subjects ingesting fish oil. Atherosclerosis 1986; 61: 129-134
• 39 Zucker ML, Bilyeu DS, Helmkamp GM, Harris WS, Dujovne CA. Effects of dietary fish oil on platelet function and plasma lipids in hyperlipoproteinemic and normal subjects. Atherosclerosis 1988; 73: 13-22
• 40 Harris WS, Dujovne CA, Zucker M, Johnson B. Effects of a low saturated fat, low cholesterol fish oil supplement in hypertriglyceridemic patients. Ann Intern Med 1988; 109: 465-469
• 41 Schechtman G, Kissebah AH. Effect of marine lipid concentrate dose on plasma lipoproteins in hypertriglyceridemic subjects. Clin Res 1987; 35: 370A
• 42 Schechtman G, Kaul S, Kissebah AH. Effect of fish oil concentrate on HDL cholesterol and apo A-l levels in hypertriglyceridemic subjects. Arteriosclerosis 1987; 7: 508a
• 43 Sprengers ED, Kluft C. Plasminogen activator inhibitors. Blood 1987; 69: 381-387
• 44 Sanders TAB, Vickers M, Haines AP. Effect on blood lipids and haemostasis of a supplement of cod-liver oil, rich in eicosapentaenoic and docosahexaenoic acids, in healthy young men. Clin Sci 1981; 61: 317-324
• 45 Barcelli U, Glas-Greenvalt P, Poliak VE. Enhancing effect of dietary supplementation with Ω-3 fatty acids on plasma fibrinolysis in normal subjects. Thromb Res 1985; 39: 307-312
• 46 Froschl H, Spannagl M, Drummer C, Landgraf-Leurs MM C, Landgraf R, Schramm W. Effect of eicosapentaenoic acid diet on humoral clotting and fibrinolysis parameters in type I diabetes mellitus. Haemostasis 1988; 18 supp (Suppl. 02) 27-28
• 47 Emeis JJ, Houwelingen AC v, Hoogen CM vd, Homstra G. A moderate fish intake increases plasminogen activator inhibitor type-1 in human volunteers. In:. Houwelingen AC v. Fish against Thrombosis?. Thesis, Leiden: 1988
• 48 Mehta J, Lawson D, Saldeen T. Reduction in plasminogen activator inhibitor-1 (PAI-1) with omega-3 polyunsaturated fatty acid (PUFA) intake. Am Heart J 1988; 116: 1201-1206
• 49 Schmidt EB, Kristensen SD, Dyerberg J. The effect of fish oil on lipids, coagulation and fibrinolysis in patients with angina pectoris. Artery 1988; 15: 316-329
• 50 Weiner BH, Ockene IS, Levine PH, Cuenoud HF, Fischer M, Johnson BF, Daoud AS, Jarmolych J, Hosmer D, Johnson MH, Natale A, Vaudreuil C, Hoogasian JJ. Inhibition of atherosclerosis by codliver oil in a hyperlipidemic swine model. N Engl J Med 1986; 315: 841-846
• 51 Davis HR, Bridenstine RT, Vessilinovitch D, Wissler RW. Fish oil inhibits development of atherosclerosis in rhesus monkeys. Artheriosclerosis 1987; 7: 441-449